Figure 3. Surface under the Cumulative Ranking Curve (SUCRA), expressed as percentages, ranking the therapeutic effects and safety of treatments for active distal ulcerative colitis patients.

For efficacy and safety assessment, the pharmacological agent with the highest SUCRA value would be the most efficacious and safe treatment. (A) Clinical remission. (B) Endoscopic remission. (C) Histopathological remission. (D) Adverse events. 5-ASA, 5-aminosalicylic acid; BDP, beclomethasone dipropionate.